Table 2. Results of multivariate Cox regression model in EGFR exon 20 insert mutation patients.
| Covariant | P value | HR (95% CI) | 95% CI | |
|---|---|---|---|---|
| Lower | Upper | |||
| Age (≤60 vs. >60) | 0.555 | 1.17 | 0.69 | 2 |
| Gender (female vs. male) | 0.090 | 0.51 | 0.23 | 1.11 |
| Smoking status (no vs. yes) | 0.992 | 1 | 0.5 | 1.98 |
| Histology (adenocarcinoma vs. non-adenocarcinoma) | 0.002 | 4.78 | 1.77 | 12.92 |
| ECOG PS (0–1 vs. ≥2) | 0.136 | 0.5 | 0.2 | 1.25 |
| Clinical stage (IIIB vs. IV) | 0.100 | 1.22 | 0.9 | 1.54 |
| Brain metastases before treatment (no vs. yes) | 0.935 | 1.04 | 0.43 | 2.49 |
| Bone metastases before treatment (no vs. yes) | 0.045 | 2.26 | 1.02 | 5.03 |
| First-line chemotherapy (pemetrexed-based vs. non-pemetrexed) | 0.432 | 0.74 | 0.35 | 1.57 |
| Second-line pemetrexed-based chemotherapy (no vs. yes) | 0.686 | 1.21 | 0.47 | 3.12 |
| EGFR exon 20 insert mutant group (A767_V769dupASV vs. S768_D770dupSVD vs. N771_H773dupNPH vs. A763_Y764insFQEA vs. others) | 0.274 | 1.1 | 0.93 | 1.32 |
| EGFR-TKI (no vs. yes) | 0.278 | 0.6 | 0.24 | 1.5 |
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.